BioVaxys Technology Corp. is pleased to announce that Dasha Enenko has been appointed as its Chief Financial Officer (“CFO”).
| VANCOUVER, BC, April 12, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) is pleased to announce that Dasha Enenko has been appointed as its Chief Financial Officer (“CFO”). Dasha is a Chartered Professional Accountant with over 12 years of accounting experience working with private, public and non-for-profit entities in a broad range of industries, including e-commerce, technology, manufacturing, food and beverages and real estate. Her responsibilities have included preparation and filling of interim and annual financial statements for publicly traded companies, working with auditors to ensure successful completeness of audit and review engagements, and helping clients with prospectus preparations. Dasha serves as CFO of Nextgen Food Robotics Corp. 
Craig Loverock, the outgoing CFO of BioVaxys, has been appointed to the Board of Directors of BioVaxys. As a financial expert, Craig will chair the audit and other relevant board committees. BioVaxys thanks Craig for his outstanding work as CFO during his tenure. Craig is filling a vacancy created by the resignation of David Wang from the Company’s Board of Directors. David is returning to reside full-time to China and will not be able to commit adequate time to serve as a director of the Company. David has been appointed as an Advisor to BioVaxys to assist the Company with business development in China, including identifying potential licensing, sales, and M&A opportunities with Chinese pharmaceutical companies. James Passin, BioVaxys CEO, stated, “We are delighted to onboard Dasha Enenko as CFO as we continue the work of advancing our product portfolio. We thank Craig for his outstanding work as CFO during his tenure and welcome him to the Board of Directors. We are excited to continue to work with former Director David Wang on opportunities in China.” About BioVaxys Technology Corp. Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). ON BEHALF OF THE BOARD Signed “James Passin” James Passin, CEO Cautionary Statements Regarding Forward Looking Information This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the animal model study, regulatory approval for a Phase I study of its BVX-1021 Vaccine Candidate in humans and the overall development of BioVaxys’ vaccines, including any haptenized SARS-Cov-2 or SARS-CoV protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys’ vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys’ business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. SOURCE: BioVaxys Technology Corp. Logo - https://mma.prnewswire.com/media/1430981/3815872/BIOVAXYS_Logo.jpg
SOURCE BioVaxys Technology Corp. | ||
Company Codes: CNSX:BIOV |
View original content:
